Carbapenem Antibacterials with Gram-Negative Activity
AssigneeFOB Synthesis, Inc.
InventorsWoo-Baeg Choi, Ewa Gruszecka-Kowalik, Hyung-Yeul Joo, Shuangpei Liu, Shuli Mao, Yongfeng Li, Deog-II Kim
Life of this patent
Estimating the term…
Abstract
The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.
Claims15
1-21. (canceled)
A method of treating a bacterial infection in a host comprising administering a therapeutic amount of a compound of Formula I:
- or a pharmaceutically acceptable salt, ester or prodrug thereof,
- wherein
- R1 and R2 are each independently selected from H or alkyl;
- P is H, OH, halogen, or hydroxyl protected by a hydroxyl protecting group;
- n is 0, 1 or 2;
- X is —(CR2)m— or —C(═O)—;
- m is 0, 1 or 2;
- Y is CN, OR, SR′ or NRR′;
- each R is independently selected from H, alkyl or haloalkyl;
- R′ is H, alkyl, NR2;
- C(═O)R;
- SO2R;
- SO2NR2;
- C(═NR)NR2;
- C(═O)NR2;
- CR2C(═O)NR2;
- C(═NR)R;
- C(═NR)NRSO2R;
- C(═NR)NRC(═O)R;
- C(═O)CR2NRSO2NR2;
- or C(═O)CR2NRC(═NR)NR2;
- and
- Z is H, alkyl, halo, CN, OR, SR′ or NRR′;
- optionally in a pharmaceutically acceptable carrier or diluent.
A method of treating a bacterial infection in a host comprising administering a therapeutic amount of a compound of Formula II:
- or a pharmaceutically acceptable salt, ester or prodrug thereof,
- wherein
- R1 and R2 are each independently selected from H or alkyl;
- P is H, OH, halogen, or hydroxyl protected by a hydroxyl protecting group;
- X is —(CR2)m— or —C(═O)—;
- m is 0, 1 or 2;
- Y is CN, OR, SR′ or NRR′;
- each R is independently selected from H, alkyl or haloalkyl;
- R′ is H, alkyl, NR2;
- C(═O)R;
- SO2R;
- SO2NR2;
- C(═NR)NR2;
- C(═O)NR2;
- CR2C(═O)NR2;
- C(═NR)R;
- C(═NR)NRSO2R;
- C(═NR)NRC(═O)R;
- C(═O)CR2NRSO2NR2;
- or C(═O)CR2NRC(═NR)NR2;
- and
- Z is H, alkyl, halo, CN, OR, SR′ or NRR′;
- optionally in a pharmaceutically acceptable carrier or diluent.
A method of treating a bacterial infection in a host comprising administering a therapeutic amount of a compound of Formula III:
- or a pharmaceutically acceptable salt, ester or prodrug thereof,
- wherein
- R1 and R2 are each independently selected from H or alkyl;
- P is H, OH, halogen, or hydroxyl protected by a hydroxyl protecting group;
- X is —(CR2)m— or —C(═O)—;
- m is 0, 1 or 2;
- Y is CN, OR, SR′ or NRR′;
- each R is independently selected from H, alkyl or haloalkyl;
- R′ is H, alkyl, NR2;
- C(═O)R;
- SO2R;
- SO2NR2;
- C(═NR)NR2;
- C(═O)NR2;
- CR2C(═O)NR2;
- C(═NR)R;
- C(═NR)NRSO2R;
- C(═NR)NRC(═O)R;
- C(═O)CR2NRSO2NR2;
- or C(═O)CR2NRC(═NR)NR2;
- and
- Z is H, alkyl, halo, CN, OR, SR′ or NRR′;
- optionally in a pharmaceutically acceptable carrier or diluent.
A method of treating a bacterial infection in a host comprising administering a therapeutic amount of a compound of Formula IV:
- or a pharmaceutically acceptable salt, ester or prodrug thereof,
- wherein
- R1, R2 and R3 are each independently selected from H or alkyl;
- P is H, OH, halogen, or hydroxyl protected by a hydroxyl protecting group;
- n is 0, 1, or 2
- X is —(CR2)m— or —C(═O)—;
- m is 0, 1 or 2;
- Y is CN, OR, SR′ or NRR′;
- each R is independently selected from H, alkyl or haloalkyl;
- R′ is H, alkyl, NR2;
- C(═O)R;
- SO2R;
- SO2NR2;
- C(═NR)NR2;
- C(═O)NR2;
- CR2C(═O)NR2;
- C(═NR)R;
- C(═NR)NRSO2R;
- C(═NR)NRC(═O)R;
- C(═O)CR2NRSO2NR2;
- or C(═O)CR2NRC(═NR)NR2;
- and
- Z is H, alkyl, halo, CN, OR, SR′ or NRR′;
- optionally in a pharmaceutically acceptable carrier or diluent.
A method of treating a bacterial infection in a host comprising administering a therapeutic amount of a compound of Formula V:
- or a pharmaceutically acceptable salt, ester or prodrug thereof,
- wherein
- R1, R2 and R3 are each independently selected from H or alkyl;
- P is H, OH, halogen, or hydroxyl protected by a hydroxyl protecting group;
- X is —(CR2)m— or —C(═O)—;
- m is 0, 1 or 2;
- Y is CN, OR, SR′ or NRR′;
- each R is independently selected from H, alkyl or haloalkyl;
- R′ is H, alkyl, NR2;
- C(═O)R;
- SO2R;
- SO2NR2;
- C(═NR)NR2;
- C(═O)NR2;
- CR2C(═O)NR2;
- C(═NR)R;
- C(═NR)NRSO2R;
- C(═NR)NRC(═O)R;
- C(═O)CR2NRSO2NR2;
- or C(═O)CR2NRC(═NR)NR2;
- and
- Z is H, alkyl, halo, CN, OR, SR′ or NRR′;
- optionally in a pharmaceutically acceptable carrier or diluent.
A method of treating a bacterial infection in a host comprising administering a therapeutic amount of a compound of Formula VI:
- or a pharmaceutically acceptable salt, ester or prodrug thereof,
- wherein
- R1 and R2 are each independently selected from H or alkyl;
- P is H, OH, halogen, or hydroxyl protected by a hydroxyl protecting group;
- X is —(CR2)m— or —C(═O)—;
- m is 0, 1 or 2;
- Y is CN, OR, SR′ or NRR′;
- each R is independently selected from H, alkyl or haloalkyl;
- R′ is H, alkyl, NR2;
- C(═O)R;
- SO2R;
- SO2NR2;
- C(═NR)NR2;
- C(═O)NR2;
- CR2C(═O)NR2;
- C(═NR)R;
- C(═NR)NRSO2R;
- C(═NR)NRC(═O)R;
- C(═O)CR2NRSO2NR2;
- or C(═O)CR2NRC(═NR)NR2;
- and
- Z is H, alkyl, halo, CN, OR, SR′ or NRR′.
A method of treating a bacterial infection in a host comprising administering a therapeutic amount of a compound selected from the group consisting of:
A method of treating a bacterial infection in a host comprising administering a therapeutic amount of a compound selected from the group consisting of:
Dependencies are inferred from the claim text.